Immunologix, Inc.

Immunologix delivers on a key unmet need, in fully realizing the vast clinical and market potential of antibody-based therapeutics.  Utilizing a proprietary in vitro method, exclusively licensed from the Medical University of South Carolina, Immunologix is uniquely positioned to derive countless fully-human antibody-based therapeutics specific for virtually any known biological target.  No other known technology platform can produce fully-human antibodies using a 100% in vitro system.

The Immunologix system provides methods for producing human monoclonal antibodies against any target including bacterial and viral antigens, as well as tumor antigens, and human autoantigens.  Immunologix's technology allows for the conversion of naïve B-cells (from a tonsillectomy or whole blood collection) to fully mature human B-cells producing the human antibody of interest. This process is far superior over traditional methods and offers low cost and reliability that exceed all other current products.

You can learn more about Immunologix by going directly to their website at: www.Immunologix.com